Multivalent Bi-Specific Nanoerythrosomes: A Two-Birds-One-Stone Approach to Combine Homologous and Active Targeting...

Area of Science:

• Biomaterials Science
• Nanomedicine
• Cardiovascular Research

Background:

• Targeted thrombolytic therapy aims to dissolve blood clots effectively.
• Combining homologous and active targeting strategies enhances drug delivery to thrombi.
• Existing therapies face challenges in specificity and off-target effects.

Purpose of the Study:

• To develop a multivalent bi-specific nanoerythrosome (mBiNE@tPA) for targeted delivery of tissue plasminogen activator (tPA).
• To evaluate the efficacy of mBiNE@tPA in achieving targeted thrombolysis both in vitro and in vivo.
• To investigate the combined homologous and active targeting mechanisms for enhanced thrombus penetration and drug release.

Main Methods:

• Fabrication of bio-inspired nanoerythrosomes using erythrocyte membranes and cyclic arginine-glycine-aspartic acid (cRGD) motifs.
• In vitro and in vivo experiments to assess thrombus accumulation, penetration, and tPA release.
• Evaluation of fibrinolysis and thrombolysis efficacy, including vascular recanalization and assessment of hemorrhagic risks in a mouse model.
• Computational modeling to elucidate the thrombolytic capabilities of mBiNE@tPA.

Main Results:

• mBiNE@tPA demonstrated sustained tPA activity during circulation.
• The system exhibited preferential thrombus accumulation and enhanced penetration.
• Combined targeting led to triggered local tPA release, resulting in efficient and selective fibrinolysis and thrombolysis.
• In vivo studies showed effective vascular recanalization with minimal hemorrhagic risks in mice.
• mBiNE@tPA outperformed single-targeting or non-targeting formulations and free tPA.

Conclusions:

• The developed nanoerythrosome platform offers a promising approach for targeted thrombolytic therapy.
• Dual targeting strategies significantly enhance the efficacy of thrombus dissolution.
• mBiNE@tPA represents a potential advancement in treating thrombotic diseases with improved safety profiles.